Literature DB >> 18093250

An orthotopic skull base model of malignant meningioma.

Gilson S Baia1, Eduard B Dinca, Tomoko Ozawa, Edna T Kimura, Michael W McDermott, C David James, Scott R VandenBerg, Anita Lal.   

Abstract

Meningioma tumor growth involves the subarachnoid space that contains the cerebrospinal fluid. Modeling tumor growth in this microenvironment has been associated with widespread leptomeningeal dissemination, which is uncharacteristic of human meningiomas. Consequently, survival times and tumor properties are varied, limiting their utility in testing experimental therapies. We report the development and characterization of a reproducible orthotopic skull-base meningioma model in athymic mice using the IOMM-Lee cell line. Localized tumor growth was obtained by using optimal cell densities and matrigel as the implantation medium. Survival times were within a narrow range of 17-21 days. The xenografts grew locally compressing surrounding brain tissue. These tumors had histopathologic characteristics of anaplastic meningiomas including high cellularity, nuclear pleomorphism, cellular pattern loss, necrosis and conspicuous mitosis. Similar to human meningiomas, considerable invasion of the dura and skull and some invasion of adjacent brain along perivascular tracts were observed. The pattern of hypoxia was also similar to human malignant meningiomas. We use bioluminescent imaging to non-invasively monitor the growth of the xenografts and determine the survival benefit from temozolomide treatment. Thus, we describe a malignant meningioma model system that will be useful for investigating the biology of meningiomas and for preclinical assessment of therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18093250     DOI: 10.1111/j.1750-3639.2007.00109.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  14 in total

1.  Yes-associated protein 1 is activated and functions as an oncogene in meningiomas.

Authors:  Gilson S Baia; Otavia L Caballero; Brent A Orr; Anita Lal; Janelle S Y Ho; Cynthia Cowdrey; Tarik Tihan; Christian Mawrin; Gregory J Riggins
Journal:  Mol Cancer Res       Date:  2012-05-22       Impact factor: 5.852

2.  Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma.

Authors:  Christine G Skibinski; Tara Williamson; Gregory J Riggins
Journal:  J Neurooncol       Date:  2018-11-09       Impact factor: 4.130

Review 3.  Meningioma mouse models.

Authors:  Michel Kalamarides; Matthieu Peyre; Marco Giovannini
Journal:  J Neurooncol       Date:  2010-08-24       Impact factor: 4.130

4.  Bioluminescence imaging of invasive intracranial xenografts: implications for translational research and targeted therapeutics of brain tumors.

Authors:  Eduard B Dinca; Ramona V Voicu; Alexandru V Ciurea
Journal:  Neurosurg Rev       Date:  2010-07-23       Impact factor: 3.042

5.  Cytotoxic effects of statins and thiazolidinediones on meningioma cells.

Authors:  Sonja Gehring; Jorge Humberto Tapia-Pérez; Elmar Kirches; Raimund Firsching; Gerburg Keilhoff; Thomas Schneider; Christian Mawrin
Journal:  J Neurooncol       Date:  2010-08-30       Impact factor: 4.130

Review 6.  Medical therapies for meningiomas.

Authors:  Patrick Y Wen; Eudocia Quant; Jan Drappatz; Rameen Beroukhim; Andrew D Norden
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

7.  Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.

Authors:  Sarah S Burns; Elena M Akhmametyeva; Janet L Oblinger; Matthew L Bush; Jie Huang; Volker Senner; Ching-Shih Chen; Abraham Jacob; D Bradley Welling; Long-Sheng Chang
Journal:  Cancer Res       Date:  2012-11-14       Impact factor: 12.701

8.  An orthotopic murine model of sinonasal malignancy.

Authors:  Alexander Gelbard; Michael E Kupferman; Samar A Jasser; Wantao Chen; Adel K El-Naggar; Jeffrey N Myers; Ehab Y Hanna
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

9.  Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma model.

Authors:  Kenichiro Iwami; Atsushi Natsume; Masasuke Ohno; Hiroaki Ikeda; Junichi Mineno; Ikuei Nukaya; Sachiko Okamoto; Hiroshi Fujiwara; Masaki Yasukawa; Hiroshi Shiku; Toshihiko Wakabayashi
Journal:  Neuro Oncol       Date:  2013-03-03       Impact factor: 12.300

10.  Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging.

Authors:  Tomoko Ozawa; C David James
Journal:  J Vis Exp       Date:  2010-07-13       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.